Skip to content

Learn

FDA peptide categories explained: Category 1, Category 2 and the 503A bulks list

By the Everlon founding team · · How we write and review health content

Quick answer FDA keeps several different lists, and the one that counts for compounding is a federal rule called the 503A bulks list; Category 1, 2 and 3 are only FDA's interim way of sorting ingredients that have been nominated for it. In July 2026 an advisory committee recommended six peptides for the bulks list, according to news reports, against the advice of FDA's own staff. As of October 2026, none of the six is on FDA's bulks list or in its Category 1; what changed, in a draft policy published for public comment on October 30, is that HHS says it does not intend to take enforcement action against compounding them when strict conditions are met; the draft is not final, and it is not approval or a listing.

The three tests an ingredient has to pass

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist or physician may compound for an individual patient from a bulk ingredient only if it passes these tests, in order:

  1. If a USP or NF monograph (an official quality standard) exists for it, the ingredient has to meet that monograph and the USP chapter on pharmacy compounding.
  2. If there is no monograph, the ingredient has to be a component of an FDA-approved drug.
  3. If there is neither, the ingredient has to be on FDA's list of bulk drug substances for 503A compounding, known as the bulks list.

The ingredient also needs a valid certificate of analysis and has to come from an FDA-registered establishment. Most peptides people search for pass neither of the first two tests, so for them the bulks list is the only lasting route. How a 503A pharmacy works is explained here.

Bulks list or category: what each one means

The bulks list is a federal regulation, 21 CFR 216.23. FDA adds to it only through notice-and-comment rulemaking: a proposed rule, a public comment period, then a final rule. The first final rule, published on February 19, 2019, listed six substances. Because the list is a rule, a press release, a committee vote or a removal from another list doesn't change it.

While FDA evaluates nominations for the list, it sorts nominated substances into interim categories under its January 2025 interim-policy guidance. Substances nominated on or after January 7, 2025 are no longer placed in any category.

What it isA federal regulationInterim category: "under evaluation"Interim categoryInterim category
What FDA says it meansThe ingredient can be used in 503A compoundingNominated with enough information to evaluate; no other list appliesFDA has identified significant safety risksNominated without enough information to evaluate
FDA's stance on compounding with itAllowed under section 503A, if the other conditions are metFDA does not intend to take action, if the conditions in its guidance are metFDA would consider taking action under its general enforcement policiesFDA would consider taking action under its general enforcement policies

Category 1 is enforcement discretion. It is not FDA approval, not a place on the bulks list and not a legal authorisation, and FDA can move a substance out of it. FDA's category list was last updated May 14, 2026.

What "removed from Category 2" means, and what it doesn't

In April 2026 FDA removed twelve substances from Category 2, effective April 22, after the nominations for them were withdrawn. On FDA's list they are BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax and thymosin beta-4 fragment (also known as TB-500).

FDA's guidance says a withdrawn nomination, and the category update that follows, "do not reflect a determination by FDA" about the nomination. So removal does not mean:

  • the substance is on the bulks list. Only a final rule does that.
  • it is in Category 1. FDA did not move these peptides there.
  • licensed pharmacies can compound it. Removal alone gives no basis. For six of the twelve, HHS's draft policy, below, proposes conditions for HHS not to take enforcement action; for the rest, removal from Category 2 still gives none.
  • FDA decided it is safe. FDA's own staff proposed in July 2026 that none of the seven substances reviewed that month be added to the list.

On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee met on seven of the twelve. News reports say it voted to recommend adding six to the bulks list and voted against a seventh, DSIP. The votes are non-binding, and FDA had posted no results as of October 21, 2026. What the vote means is explained here.

Pending FDA rulemaking, the six are on neither FDA's bulks list nor its Category 1. As of October 21, 2026, FDA's category list was unchanged since May 14, and a search of the Federal Register found no proposed rule to add them.

HHS's October 2026 draft policy for the six

HHS, the department FDA belongs to, has drafted an enforcement-discretion policy for exactly these six: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The National Community Pharmacists Association reported it on October 29, 2026, and HHS published it as a draft for comment (Federal Register, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; October 30, 2026), with a two-week comment period; the notice says it is "not binding on HHS or the public." Emideltide (DSIP), the one the committee turned down, is not covered.

The draft says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with one of the six when every condition is met. The routes and conditions are set out here.

Where it sits among FDA's lists:

  • It is enforcement discretion, like Category 1. It doesn't amend 21 CFR 216.23 or add anything to the bulks list.
  • It is a draft, and temporary. As drafted, it would run until a final rule decides each peptide's place on the bulks list, and HHS says it may revisit it if "a safety signal or product quality issue arises."

Why GHK-Cu is the exception

FDA's May 14, 2026 list puts GHK-Cu in Category 1 "except for injectable routes of administration", so a topical cream, for example, is covered. It had been removed on April 22 when its nominations were withdrawn, then added back after a nominator clarified on May 5 that it was withdrawing only the injectable route. Injectable GHK-Cu is in no category. FDA says it intends to consult its advisory committee about GHK-Cu before the end of February 2027, along with four other substances.

Compounded medications are not FDA-approved, and a place on one of FDA's lists doesn't change that.

Is this right for me?

This page is for you if someone has offered you one of the six peptides, or you've read that one is now allowed, and you want to know where it stands. It can't tell you whether a treatment suits your health; only a licensed provider who knows your history can, and the answer may be no.

What you can do now:

  • Ask the seller what it relies on: one of the three tests, Category 1, or HHS's draft policy, and if the policy, how it meets each condition.
  • Ask which state board of pharmacy licenses the pharmacy, and look it up through FDA's BeSafeRx state links.
  • Treat a "research use only" label as a warning, not a medicine. What that label means is explained here.
  • Take the goal that brought you here to your own doctor.

Whatever the rules allow, a licensed provider in your state would still review your health history and decide whether anything fits you.

How it works

  1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
  2. Hear from us only if Everlon offers one of them. We write about availability and nothing else, and you can unsubscribe anytime.
  3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If Everlon ever offers one, a provider licensed in your state reviews your health history first and can decline.

FAQ

Does Category 1 mean FDA approval? No. Category 1 means FDA says it does not intend to take action against compounding with the substance while it finishes its evaluation, if conditions are met. It is not approval, and FDA can change it.

Is a Category 2 substance illegal? It's a policy category, not a ban written into law. FDA says it would consider taking action against compounding with Category 2 substances under its general enforcement policies.

Did any of the six peptides move to Category 1 in 2026? No. As of October 21, 2026, none of the six was in Category 1, 2 or 3 on FDA's May 14, 2026 list. HHS's draft enforcement-discretion policy is a separate document. GHK-Cu, except for injectable routes, is in Category 1, and it isn't one of the six.

What is HHS's draft peptide policy? A draft HHS enforcement-discretion policy, published for public comment on October 30, 2026, for BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The draft says HHS does not intend to take enforcement action against compounding them when every condition is met. It is not final, it is not approval, it doesn't change FDA's lists, and HHS may revisit it.

How does a substance get onto the bulks list? Through a proposed rule, public comments and a final rule. The first round took about 26 months, and FDA has published no timetable for the six.

What this means for you

As of October 2026, none of these six peptides is on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with for patients, and only FDA rulemaking changes that. Until a final rule decides, HHS has proposed, in a draft policy, not to take enforcement action against them when its conditions are met; the draft is not final and may change. Compounded medications are not FDA-approved, and products sold online as "research use only" aren't made for people.

HHS's 2026 draft peptide compounding policy, explained has the routes and conditions, and the July 2026 FDA peptide vote, explained covers what came before it.

Safety information

None of the six peptides is an FDA-approved drug. Compounded medications are not FDA-approved either; the difference is that a licensed pharmacy makes them for one patient, on a prescription.

What FDA has said about the six, on its safety page (current as of April 22, 2026):

  • Immune reactions and impurities. For several of them, FDA says compounded drugs may pose a risk of immunogenicity (an immune reaction to the peptide) and may have peptide-related impurities.
  • Little or no safety information. For BPC-157, Semax and Epitalon, FDA says it has identified no or limited safety information and lacks the information to know whether the drug would cause harm when given to people. For TB-500, MOTS-c and KPV, it says it has not identified any human exposure data.
  • Not a verdict either way. These statements are not a finding that any of them is harmful, and not a finding that any of them is safe.

Products sold online as "research use only" are a different, unregulated market that carries additional dangers: no licensed pharmacy makes them for a patient, so no pharmacy quality standards apply.

If you have used a product like this and feel unwell, stop and tell a doctor exactly what you took. Seek care at once for trouble breathing, swelling of the face or throat, or a spreading rash. If this is a medical emergency, call 911.

Sources

  • 21 U.S.C. 353a, Pharmacy compounding. law.cornell.edu, accessed 2026-10-06
  • 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
  • FDA. List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act (final rule). Federal Register. 2019;84:4696. FR Doc. 2019-02367. February 19, 2019. federalregister.gov, accessed 2026-10-06
  • FDA. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (guidance for industry). January 2025. fda.gov, accessed 2026-10-06
  • FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Content current as of May 14, 2026. fda.gov, accessed 2026-10-21
  • FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-21
  • FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Version updated April 22, 2026, archived copy. web.archive.org, accessed 2026-10-06
  • FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. fda.gov, accessed 2026-10-21
  • FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Content current as of August 6, 2026. fda.gov, accessed 2026-10-21
  • FDA. Briefing Document, Pharmacy Compounding Advisory Committee, July 23–24, 2026: Introduction. fda.gov, accessed 2026-10-06
  • FDA. Meeting of the Pharmacy Compounding Advisory Committee (early announcement of a meeting before the end of February 2027). Content current as of April 15, 2026. fda.gov, accessed 2026-10-21
  • ABC News. FDA advisers narrowly vote to add 6 peptides to drug compounding list (news report of the vote; FDA had not posted vote results). abcnews.com, accessed 2026-10-06
  • HHS. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix B; no issue or effective date printed). hhs.gov, accessed 2026-10-29
  • National Community Pharmacists Association (NCPA). Newsroom report on enforcement discretion for compounding six peptides. October 29, 2026 (news report). ncpa.org, accessed 2026-10-29
  • FDA. BeSafeRx: Locate a State-Licensed Online Pharmacy. fda.gov, accessed 2026-10-06

Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.